Quantgene Demonstrates Game-Changing Sequencing Precision in GENES, A Leading Scientific Journal

Quantgene | June 08, 2021

Quantgene, biotechnology, cloud, and AI company located in Santa Monica, CA, and Berlin, Germany, has demonstrated the most exact gene sequencing yet published in the industry, as shown in the February edition of GENES, a major scientific journal in medical genomics.

"Precision Genomics is revolutionizing medicine, but it is being hampered by a lack of rapid, accurate, and easily accessible technology," said Jo Bhakdi, CEO of Quantgene. "Today, the protection of human life is dependent on the advancement of precision genomics, and we are excited to open a new chapter in genomic testing and less invasive cancer screening."

DEEPGENTM reduced error rates on Illumina NovaSeq platforms hundreds of times by integrating new chemistry with large-scale cloud processing, mathematically enhanced error reduction, and statistically optimized genomic mapping, signaling an innovative approach ahead for cancer testing. Quantgene's latest innovation is a significant step forward in evidence-based healthcare and precision medicine.

Quantgene's DEEPGEN technology was thoroughly investigated in its peer-reviewed publication, which included a series of technical validations. According to the publication, the system detects somatic variations in DNA fragments with an accuracy of more than 1 in 1000 fragments, with high repeatability and very low false-positive results. This degree of accuracy has previously only been proven in a peer-reviewed setting for systems that examined a small number of genomic regions. DEEPGEN's technology covers around 70,000 locations and includes a wide range of FDA-approved cancer targets.

The results of Quantgene represent a significant advance in the identification of cancer signals in the blood using liquid biopsy and next-generation sequencing technology. Liquid biopsy can be a less invasive and more accurate method of diagnosing different forms of cancer. In oncology, it may also be used to aid physicians in early cancer detection, companion diagnostics, and identifying minimum residual disease.

"This is a crucial step forward in precision medicine. Quantgene provides the industry with a more powerful tool to diagnose cancer and other serious diseases earlier than ever before by achieving single-molecule sequencing precision ", said Jo Bhakdi, CEO of Quantgene.

About Quantgene
Quantgene has emerged as a technical leader in single-molecule precision sequencing over the last six years. To better protect patients from cancer, the company combines deep genomic, cloud, and AI technologies with innovative preventative medicine solutions. Its objective is to increase the healthy human lifespan by ten years within the next ten years.


Hycult Biotech is a leading world-class manufacturer of research reagents in the field of innate immunity. Our products are co-developed with researchers around the globe. By connecting science with disease, these products offer innovative research solutions that enable better treatment, monitoring and prevention.

Other News

Evonetix Granted Patent for Technology Enabling Thermally-Controlled DNA Synthesis

evonetix | April 04, 2022

EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted patent EP3551331B1 in Europe for its proprietary thermal control technology for DNA synthesis, as well as the design and manufacture of its silicon chips. This patent extends Evonetix’s IP portfolio and is a key step in the Company’s strategy to develop a benchtop DNA synthesis platform, to change how DNA is accessed, made, and used. Evonetix’s novel approach to parallel DNA synthesis is underpinned by precise, independent, control of temperature at thousands of individual synthesis sites across the surface of a silicon chip. In contrast to conventional approaches, which use acid deprotection to control the synthesis cycle, Evonetix uses thermal control with semiconductor-based arrays. This offers greater accuracy and selectivity to deprotect sequences at the correct point to add the next nucleotide and remove mismatching sequences. Thermal control of DNA synthesis enables highly parallel synthesis and gives the ability to work through sequences that are hard to synthesise using conventional techniques and to remove errors during the assembly of gene sequences through temperature mediated error removal. There is currently an unmet need in the synthetic biology industry for long, accurate, DNA sequences, and the ability to remove errors during assembly allows researchers to achieve longer strands of DNA, and run applications such as gene synthesis, CRISPR screening, and protein engineering. Securing this patent to cover our core technology adds further strength to our IP portfolio and underlines Evonetix’s position as leaders in our field. Our technology will give researchers the capabilities of service centres in their own lab, accelerating the advancement of synthetic biology and opening new possibilities in this exciting market.” Matthew Hayes, Chief Technology Officer at Evonetix.

Read More


Bakar Labs and the Cystic Fibrosis Foundation Support Entrepreneurs to Develop New Genetic Therapies for CF

Bakar Labs | April 19, 2022

Bakar Labs, the incubator at UC Berkeley's Bakar BioEnginuity Hub (BBH), announced today a unique collaboration with the Cystic Fibrosis Foundation to accelerate the application of new technologies for the treatment of cystic fibrosis. The CF Foundation is sponsoring a "Golden Ticket" competition at the new incubator and is encouraging companies with emerging technology in gene editing, gene delivery, and gene therapy/gene insertion that may work in CF to apply. Applications open Monday, May 2. Up to three potential winners will be provided lab space and facilities at Bakar Labs. In addition to lab and office space, companies will have access to the extensive resources of the CF Foundation, including scientific experts and advice, lab/research tools and techniques, an extensive patient registry, clinical trial design support, and a Therapeutics Development Network of over 90 clinical trial sites in the US. Working with the CF Foundation entirely fits with the spirit of entrepreneurship to benefit society, Our double bottom line at Bakar Labs emphasizes public good on an equal basis with the potential for profit." Regis Kelly, PhD, OBE, director of Bakar Labs and executive director at QB3. This collaboration is inspiring, Students and professors will see the potential of entrepreneurship fused with the resources and mission of a major patient advocacy organization. It will be a tremendous example that could well spur partnerships in a broad range of areas." David Schaffer, PhD, executive director of BBH. Schaffer is Hubbard Howe Distinguished Professor at UC Berkeley, with appointments in the departments of chemical and biomolecular engineering, bioengineering, and molecular and cell biology. A focus on entrepreneurship for the public good is now widely seen by many philanthropies and investors as a valuable and effective complement to their support of academic scholarship. The CF Foundation has achieved global admiration for its support of disease-related research efforts, not only by scientists in academic labs but by entrepreneurs in startup companies. About the Bakar BioEnginuity Hub The Bakar BioEnginuity Hub empowers fearless founders — and founders in the making — to realize bold solutions to our world's most pressing problems. Focused on people working at the convergence of the life sciences with the physical, engineering, and data sciences, the Bakar BioEnginuity Hub provides the intellectual, entrepreneurial, and community resources needed to learn and then to launch their own ventures. The Bakar BioEnginuity Hub is located on the UC Berkeley campus in the stunning Woo Hon Fai Hall. About Bakar Labs Bakar Labs is the flagship life science-focused incubator at UC Berkeley's Bakar BioEnginuity Hub. Operated by QB3, Bakar Labs provides extensive equipment, lab and office facilities, and a community of like-minded entrepreneurs to helps startups grow. Bakar Labs can support as many as 50 early-stage companies from around the world focused on translating life science based innovations that promise to improve human health.

Read More


Genetic Leap and Astellas Establish Research Collaboration to Develop RNA-targeted Small Molecules for Oncology Target

Genetic Leap | March 11, 2022

Genetic Leap today announced a research collaboration agreement with Astellas Pharma, Inc. to develop novel RNA-targeted small molecule therapeutic candidates against an undisclosed oncology target. Under the terms of the agreement, Genetic Leap will deploy its platform to discover and validate RNA-targeted small molecules against an undisclosed oncology target selected by Astellas. The agreement provides Astellas with certain rights to intellectual property on candidates discovered and developed under the collaboration that are directed against the program target. Further details of the collaboration were not disclosed. About Genetic Leap Genetic Leap's vision is to lead the next giant leap in human healthcare by developing today the incredible therapeutics of the future. To accomplish this, Genetic Leap built paradigm-shifting AI technologies that find the causal factors in disease and correct these factors with precision RNA therapy that is safe, convenient, and reversible. The company is leveraging its platform to advance a pipeline that spans internal as well as partnered programs, across both novel and known (but traditionally undruggable) targets.

Read More


Enzychem Lifesciences Announces Formation of Corporate Advisory Committee

Enzychem Lifesciences | March 03, 2022

Enzychem Lifesciences a clinical-stage biotechnology company, announced today the formation of its Corporate Advisory Committee. Composed of four eminent physicians, its mission is to support and guide corporate activities including technology transfer for its lead compound, EC-18, seeking strategic partnerships, and preparing U.S. phase 3 clinical trials to successfully commercialize EC-18. After the completion of its phase 2 U.S. clinical trial with EC-18 in Chemoradiation–induced Oral Mucositis (CRIOM), Enzychem is actively negotiating licensing deals with several partnering candidates while also preparing a phase 3 trial under a US FDA IND. To reinforce such corporate initiatives, and to start supporting the company’s next stage activities, Enzychem has formed the Corporate Advisory Committee. Enzychem Lifesciences recognizes the need for engagement of key opinion leaders at an earlier stage in the process of developing new therapeutics for a large population with high unmet needs such as Chemoradiation-induced Oral Mucositis (CRIOM). Enzychem is proactively bringing more experts to the company to strengthen its new drug development capabilities. The newly appointed corporate advisors will actively influence the development of strong business strategies to successfully meet corporate objectives. The four physicians appointed are Dr. Alexander Fleming, a former FDA reviewer and supervisory medical officer, as head of the metabolic group, Dr. Frank Castellana, a market value assessment expert, Dr. Joe McMenamin, a health lawyer, and Dr. Richard Hamrick, a former healthcare provider executive. Based on their extensive experience, the corporate advisors will assist Enzychem in accomplishing its business milestones. For two years, until 2018, Dr. Fleming served as Enzychem’s Chief Technology Officer (CTO). During his term, Dr. Fleming had recommended CRIOM as the lead indication for EC-18 and introduced Dr. Steve Sonis of Harvard School of Dental Medicine as Enzychem’s key advisor for the U.S. phase 2 CRIOM Study. Enzychem Lifesciences is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic, and inflammatory diseases. Founded in 1999, the company’s lead compound, EC-18, acts as an immunomodulator, facilitating the resolution of inflammation and the early return to immune homeostasis. Enzychem is headquartered in South Korea, with an office in the United States.

Read More


Hycult Biotech is a leading world-class manufacturer of research reagents in the field of innate immunity. Our products are co-developed with researchers around the globe. By connecting science with disease, these products offer innovative research solutions that enable better treatment, monitoring and prevention.